99% high Purity Raw Material Drug , BMS -790052 Daclatasvir Powder

Basic Information
Place of Origin: China
Brand Name: Senwayer Brand
Certification: ISO, 9001, USP
Model Number: 1009119-64-5
Minimum Order Quantity: 10grams
Price: Discount is possible if your order is big enough
Packaging Details: 10g, 20g, 50g , 100g, 500g. 1kg, 10kg
Delivery Time: within 2 working days
Payment Terms: T/T in advance, Money Gram, Western Union, Bank Transfer.
Supply Ability: 1000kg/month
Detail Information
CAS: 1009119-64-5 Apparence: White Powder
Purity: 99%
High Light:

pharmaceutical raw material


medical raw material

Product Description


99% high Purity Raw Material Drug , BMS -790052 Daclatasvir Powder


Quick detail

Name: Daclatasvir (BMS-790052)
CAS No.: 1009119-64-5
Formula: C40H50N8O6
Molecular Weight: 738.875
Synonyms: BMS-790052;
Density: 1.25 g/cm3
Boiling Point: 1071.239 °C at 760 mmHg
Flash Point: 601.664 °C
Appearance: White Powder


Daclatasvir Description

Daclatasvir (USAN, formerly BMS-790052, trade name Daklinza) is a drug for the treatment of hepatitis C (HCV).


Daclatasvir has been tested in combination regimens with pegylated interferon and ribavirin, as well as with other direct-acting antiviral agents including asunaprevir and sofosbuvir.
It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system.
There has been significant controversy over the price that Bristol-Myers Squibb has chosen to charge for the drug.


Daclatasvir Uses

Uses 1

Daclatasvir (brand name Daklinza) is a new medication used to treat hepatitis C.


Uses 2
Daclatasvir is an antiviral medicine that prevents hepatitis C virus (HCV) from multiplying in your body.
Uses 3 Daclatasvir is used to treat genotype 3 chronic hepatitis C in adults without cirrhosis. This medicine is given together with another drug called sofosbuvir.
Uses 4
For others, daclatasvir can shorten treatment when added to pegylated interferon and ribavirin. Successful treatment reduces the risk of long-term complications of hepatitis C such as liver cancer or needing a liver transplant.


Daclatasvir Work

  1. Daclatasvir is one of the new direct-acting antiviral drugs that target different steps of the hepatitis C virus (HCV) lifecycle. It is the first-ever approved HCV NS5A replication complex inhibitor, meaning it interferes with a protein the virus uses to reproduce.
  2. Daclatasvir should be combined with other medications, which may include other direct-acting antivirals that work differently – sofosbuvir (Sovaldi) or the HCV protease inhibitor asunaprevir (Sunvepra) – or pegylated interferon and ribavirin.


How effective is daclatasvir

Daclatasvir works better for some people than for others. Several factors predict how well someone will respond, including HCV genotype, extent of liver damage and previous treatment history. People with liver cirrhosis do not respond as well as those with mild or moderate liver fibrosis. Depending on which drugs daclatasvir is combined with, people who are new to treatment may have a better chance of being cured than those with little or no response to prior treatment.

However, factors that traditionally predict poor response to interferon-based therapy do not make as much difference with interferon-free treatment. These factors may be overcome by prolonging treatment or by adding another direct-acting antiviral or ribavirin.


99% high Purity Raw Material Drug , BMS -790052 Daclatasvir Powder 0

Contact Details
Abby Xiang

Phone Number : +8617764031156

WhatsApp : +8617764031156